A recent randomized clinical trial evaluated the impact of CYP2D6 genotype-guided opioid prescribing on postoperative pain management. While the approach improved concordance between prescribed opioids and metabolic phenotype, it did not result in significant differences in pain intensity or opioid use compared to usual care.
Background
Postoperative pain management is critical for patient recovery and can significantly affect outcomes. The CYP2D6 enzyme plays a crucial role in opioid metabolism, and genotype-guided prescribing aims to optimize opioid selection based on individual metabolic profiles. Understanding the effectiveness of this approach is essential for improving pain management strategies in surgical patients.
Data Highlights
{'Silverman Integrated Analgesic Assessment Score': {'genotype_guided': 'Verify and correct the reported score.', 'control': 'Verify and correct the reported score.'}}
Key Findings
{'add_note': 'Include a note on the lack of significant differences in pain outcomes.'}
Clinical Implications
{'emphasize_multimodal': 'Strengthen the emphasis on multimodal pain management strategies.'}
Conclusion
{'strengthen_research_need': 'Make the need for further research more prominent.'}
A large audit of biomedical publications suggests fabricated references are increasingly appearing in peer-reviewed papers — often in ways that are difficult for reviewers and readers to detect.
